• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

镰状细胞病成人死亡的血流动力学预测因素。

Hemodynamic predictors of mortality in adults with sickle cell disease.

机构信息

Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.

出版信息

Am J Respir Crit Care Med. 2013 Apr 15;187(8):840-7. doi: 10.1164/rccm.201207-1222OC.

DOI:10.1164/rccm.201207-1222OC
PMID:23348978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3707372/
Abstract

BACKGROUND

Pulmonary hypertension (PH) in adults with sickle cell disease (SCD) is associated with early mortality, but no prior studies have evaluated quantitative relationships of mortality to physiological measures of pre- and postcapillary PH.

OBJECTIVES

To identify risk factors associated with mortality and to estimate the expected survival in a cohort of patients with SCD with PH documented by right heart catheterization.

METHODS

Nine-year follow-up data (median, 4.7 yr) from the National Institutes of Health SCD PH screening study are reported. A total of 529 adults with SCD were screened by echocardiography between 2001 and 2010 with no exclusion criteria. Hemodynamic data were collected from 84 patients. PH was defined as mean pulmonary artery pressure (PAP) ≥ 25 mm Hg. Survival rates were estimated by the Kaplan-Meier method, and mortality risk factors were analyzed by the Cox proportional hazards regression.

MEASUREMENTS AND MAIN RESULTS

Specific hemodynamic variables were independently related to mortality: mean PAP (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.05-2.45 per 10 mm Hg increase; P = 0.027), diastolic PAP (HR, 1.83; 95% CI, 1.09-3.08 per 10 mm Hg increase; P = 0.022), diastolic PAP - pulmonary capillary wedge pressure (HR, 2.19; 95% CI, 1.23-3.89 per 10 mm Hg increase; P = 0.008), transpulmonary gradient (HR, 1.78; 95% CI, 1.14-2.79 per 10 mm Hg increase; P = 0.011), and pulmonary vascular resistance (HR, 1.44; 95% CI, 1.09-1.89 per Wood unit increase; P = 0.009) as risk factors for mortality.

CONCLUSIONS

Mortality in adults with SCD and PH is proportional to the physiological severity of precapillary PH, demonstrating its prognostic and clinical relevance despite anemia-induced high cardiac output and less severely elevated pulmonary vascular resistance.

摘要

背景

成人镰状细胞病(SCD)合并肺动脉高压(PH)与早期死亡率相关,但之前的研究并未评估死亡率与毛细血管前和毛细血管后 PH 的生理测量值之间的定量关系。

目的

确定与死亡率相关的危险因素,并估计通过右心导管检查确诊为 PH 的 SCD 患者队列的预期生存率。

方法

报告了美国国立卫生研究院 SCD PH 筛查研究的 9 年随访数据(中位数,4.7 年)。2001 年至 2010 年期间,通过超声心动图对 529 例 SCD 成人进行了筛查,无排除标准。从 84 例患者中收集了血流动力学数据。肺动脉平均压(PAP)≥25mmHg 定义为 PH。通过 Kaplan-Meier 法估计生存率,通过 Cox 比例风险回归分析死亡率的危险因素。

测量和主要结果

特定的血流动力学变量与死亡率独立相关:平均 PAP(危险比 [HR],每增加 10mmHg 为 1.61;95%置信区间 [CI],1.05-2.45;P=0.027)、舒张期 PAP(HR,每增加 10mmHg 为 1.83;95%CI,1.09-3.08;P=0.022)、舒张期 PAP-肺毛细血管楔压(HR,每增加 10mmHg 为 2.19;95%CI,1.23-3.89;P=0.008)、肺跨压梯度(HR,每增加 10mmHg 为 1.78;95%CI,1.14-2.79;P=0.011)和肺血管阻力(HR,每增加 1 个 Wood 单位为 1.44;95%CI,1.09-1.89;P=0.009)是死亡的危险因素。

结论

SCD 合并 PH 的成年人死亡率与毛细血管前 PH 的生理严重程度成正比,尽管贫血导致心输出量增加和肺血管阻力升高不那么严重,但仍显示出其预后和临床相关性。

相似文献

1
Hemodynamic predictors of mortality in adults with sickle cell disease.镰状细胞病成人死亡的血流动力学预测因素。
Am J Respir Crit Care Med. 2013 Apr 15;187(8):840-7. doi: 10.1164/rccm.201207-1222OC.
2
Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival.镰状细胞病中的肺动脉高压:心导管检查结果与生存情况
Blood. 2003 Feb 15;101(4):1257-61. doi: 10.1182/blood-2002-03-0948. Epub 2002 Oct 3.
3
The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease.舒张期肺压差不能预测左心疾病所致肺动脉高压患者的生存率。
JACC Heart Fail. 2015 Jan;3(1):9-16. doi: 10.1016/j.jchf.2014.07.010. Epub 2014 Nov 12.
4
Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.系统性硬化症患者的临界平均肺动脉压:跨肺压差可预测发生肺动脉高压的风险。
Arthritis Rheum. 2013 Apr;65(4):1074-84. doi: 10.1002/art.37838.
5
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.美国胸科学会官方临床实践指南:镰状细胞病相关肺动脉高压的诊断、风险分层和管理。
Am J Respir Crit Care Med. 2014 Mar 15;189(6):727-40. doi: 10.1164/rccm.201401-0065ST.
6
Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure.左心衰竭中肺动脉高压的血流动力学表型分析
Circ Heart Fail. 2017 Sep;10(9). doi: 10.1161/CIRCHEARTFAILURE.117.004082.
7
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease.镰状细胞病中N末端前脑钠肽水平与死亡风险
JAMA. 2006 Jul 19;296(3):310-8. doi: 10.1001/jama.296.3.310.
8
Echocardiographic and Hemodynamic Predictors of Survival in Precapillary Pulmonary Hypertension: Seven-Year Follow-Up.毛细血管前性肺动脉高压患者生存的超声心动图和血流动力学预测因素:七年随访
Circ Cardiovasc Imaging. 2015 Jun;8(6). doi: 10.1161/CIRCIMAGING.114.002107.
9
Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection Fraction.肺动脉容量是射血分数保留的心力衰竭患者死亡率的重要预测指标。
JACC Heart Fail. 2015 Jun;3(6):467-474. doi: 10.1016/j.jchf.2015.01.013.
10
Pulmonary artery occlusion pressure may overdiagnose pulmonary artery hypertension in sickle cell disease.肺动脉闭塞压可能会误诊镰状细胞病中的肺动脉高压。
Clin Cardiol. 2013 Sep;36(9):524-30. doi: 10.1002/clc.22153. Epub 2013 Jul 24.

引用本文的文献

1
Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with Sickle Cell Disease and Increased Tricuspid Regurgitant Jet Velocity: a Randomized Controlled Trial.评估L-精氨酸对镰状细胞病合并三尖瓣反流喷射速度增加患儿的可能疗效和安全性的临床研究:一项随机对照试验
Paediatr Drugs. 2025 Jun 17. doi: 10.1007/s40272-025-00701-w.
2
Correlation of Pulmonary Arterial Hypertension with Laboratory Parameters in Sickle Cell Disease- A Retrospective Study.镰状细胞病中肺动脉高压与实验室参数的相关性——一项回顾性研究
Indian J Hematol Blood Transfus. 2025 Apr;41(2):377-382. doi: 10.1007/s12288-024-01772-4. Epub 2024 May 8.
3
Pulmonary Hypertension in Sickle Cell Disease: Novel Findings of Gene Polymorphisms Related to Pathophysiology.镰状细胞病中的肺动脉高压:与病理生理学相关的基因多态性的新发现。
Int J Mol Sci. 2024 Apr 27;25(9):4792. doi: 10.3390/ijms25094792.
4
Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry.镰状细胞病成人死亡率:镰状细胞病实施联合会(SCDIC)登记处的结果。
Am J Hematol. 2024 May;99(5):900-909. doi: 10.1002/ajh.27279. Epub 2024 Mar 7.
5
Dual-energy computed tomography to detect early pulmonary vascular changes in children with sickle cell disease: a pilot study.双能计算机断层扫描检测镰状细胞病患儿早期肺血管变化:一项试点研究。
Front Pediatr. 2023 Aug 30;11:1221977. doi: 10.3389/fped.2023.1221977. eCollection 2023.
6
The Cardiopulmonary Complications of Sickle Cell Disease.镰状细胞病的心肺并发症。
Hematol Oncol Clin North Am. 2022 Dec;36(6):1217-1237. doi: 10.1016/j.hoc.2022.07.014.
7
Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.与血液系统恶性肿瘤患者相比,镰状细胞病患者的心脏、肺和肾脏的治愈性疗法的长期健康影响。
J Clin Med. 2022 May 31;11(11):3118. doi: 10.3390/jcm11113118.
8
Arginine Therapy and Cardiopulmonary Hemodynamics in Hospitalized Children with Sickle Cell Anemia: A Prospective, Double-blinded, Randomized Placebo-controlled Clinical Trial.精氨酸治疗与镰状细胞贫血住院儿童的心肺血流动力学:一项前瞻性、双盲、随机安慰剂对照临床试验。
Am J Respir Crit Care Med. 2022 Jul 1;206(1):70-80. doi: 10.1164/rccm.202108-1930OC.
9
Endothelial superoxide dismutase 2 is decreased in sickle cell disease and regulates fibronectin processing.镰状细胞病中内皮型超氧化物歧化酶 2 减少,并调节纤维连接蛋白的加工。
Function (Oxf). 2022 Feb 17;3(2):zqac005. doi: 10.1093/function/zqac005. eCollection 2022.
10
Sickle Cell Disease-Induced Pulmonary Hypertension: A Review of Pathophysiology, Management, and Current Literature.镰状细胞病所致肺动脉高压:病理生理学、管理及当前文献综述
Pulse (Basel). 2021 Sep 23;9(3-4):57-63. doi: 10.1159/000519101. eCollection 2021 Dec.

本文引用的文献

1
Mortality in adults with sickle cell disease and pulmonary hypertension.患有镰状细胞病和肺动脉高压的成年人的死亡率。
JAMA. 2012 Mar 28;307(12):1254-6. doi: 10.1001/jama.2012.358.
2
Pulmonary hypertension in patients with sickle cell disease: not so frequent but so different.镰状细胞病患者的肺动脉高压:虽不常见但却独特。
Eur Respir J. 2012 Jan;39(1):3-4. doi: 10.1183/09031936.00119811.
3
Guilt by association.因关联而有罪。
Blood. 2011 Oct 6;118(14):3758-9. doi: 10.1182/blood-2011-08-370338.
4
Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease.右心导管术诊断镰状细胞病中的肺动脉高压。
Eur Respir J. 2012 Jan;39(1):112-8. doi: 10.1183/09031936.00134410. Epub 2011 Jul 20.
5
A hemodynamic study of pulmonary hypertension in sickle cell disease.镰状细胞病中肺动脉高压的血液动力学研究。
N Engl J Med. 2011 Jul 7;365(1):44-53. doi: 10.1056/NEJMoa1005565.
6
An elevated estimated pulmonary arterial systolic pressure, whenever measured, is associated with excess mortality in adults with sickle cell disease.无论何时测量,估计的肺动脉收缩压升高都与镰状细胞病成人患者的额外死亡率相关。
Acta Haematol. 2011;125(4):225-9. doi: 10.1159/000323464. Epub 2011 Feb 1.
7
Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine.重构镰状细胞病:从循证医学的角度对肺动脉高压的“高溶血范例”进行基于数据的分析。
Am J Hematol. 2011 Feb;86(2):123-54. doi: 10.1002/ajh.21952.
8
[A new clinical classification of pulmonary hypertension].[肺动脉高压的一种新临床分类]
Bull Acad Natl Med. 2009 Nov;193(8):1897-909.
9
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).预测肺动脉高压患者的生存情况:来自评估早期和长期肺动脉高压疾病管理登记研究(REVEAL)的见解。
Circulation. 2010 Jul 13;122(2):164-72. doi: 10.1161/CIRCULATIONAHA.109.898122. Epub 2010 Jun 28.
10
Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension.胆红素作为肺动脉高压患者的预后标志物。
BMC Pulm Med. 2010 Apr 22;10:22. doi: 10.1186/1471-2466-10-22.